30 - References

References

360 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 References

1. Berman RM, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47:351–354.
2. Zarate CA, Jr., et al. A randomized trial of an N-­methyl-­D-­aspartate antagonist in treatment-­resistant major depression. Arch Gen Psychiatry 2006; 63:856–864.
3. Diazgranados N, et al. A randomized add-­on trial of an N-­methyl-­D-­aspartate antagonist in treatment-­resistant bipolar depression. Arch Gen Psychiatry 2010; 67:793–802.
4. Murrough JW, et al. Antidepressant efficacy of ketamine in treatment-­resistant major depression: a two-­site randomized controlled trial. Am J Psychiatry 2013; 170:1134–1142.
5. Singh JB, et al. A double-­blind, randomized, placebo-­controlled, dose-­frequency study of intravenous ketamine in patients with treatment-­ resistant depression. Am J Psychiatry 2016; 173:816–826.
6. Fava M, et al. Double-­blind, placebo-­controlled, dose-­ranging trial of intravenous ketamine as adjunctive therapy in treatment-­resistant depression (TRD). Mol Psychiatry 2020; 25:1592–1603.
7. Li S, et al. Effects of ketamine and esketamine on preventing postpartum depression after cesarean delivery: a meta-­analysis. J Affect Disord 2024; 351:720–728.
8. Ma S, et al. Association between esketamine interventions and postpartum depression and analgesia following cesarean delivery: a systematic review and meta-­analysis. Am J Obstet Gynecol MFM 2024; 6:101241.
9. Wang S, et al. Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial. BMJ 2024; 385:e078218.
10. Ren L, et al. Comparative efficacy and tolerability of different anesthetics in electroconvulsive therapy for major depressive disorder: a systematic review and network meta-­analysis. J Psychiatr Res 2024; 171:116–125.
11. de A Simoes Moreira D, et al. Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: a systematic review and meta-­analysis. J Affect Disord 2023; 330:227–238.
12. Menon V, et al. Ketamine vs electroconvulsive therapy for major depressive episode: a systematic review and meta-­analysis. JAMA Psychiatry 2023; 80:639–642.
13. Reif A, et al. Esketamine nasal spray versus quetiapine for treatment-­resistant depression. N Engl J Med 2023; 389:1298–1309.
14. Lener MS, et al. Glutamate and gamma-­aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol Psychiatry 2017; 81:886–897.
15. Terao I, et al. Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-­resistant unipolar depression: a systematic review and network meta-­analysis. J Affect Disord 2024; 346:49–56.
16. Seshadri A, et al. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for major depression: a systematic review and meta-­analysis. J Affect Disord 2024; 356:379–384.
17. Glue P, et al. Safety and efficacy of extended release ketamine tablets in patients with treatment-­resistant depression and anxiety: open label pilot study. Ther Adv Psychopharmacol 2020; 10:2045125320922474.
18. Beck K, et al. Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-­analysis. JAMA Netw Open 2020; 3:e204693.
19. Anderson DJ, et al. Ketamine-­induced cystitis: a comprehensive review of the urologic effects of this psychoactive drug. Health Psychol Res 2022; 10:38247.
20. Chang M, et  al. Ketamine cystitis following ketamine therapy for treatment-­resistant depression  -­ case report. BMC Psychiatry 2024; 24:9.
21. Loo CK, et al. Placebo-­controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand 2016; 134:48–56.
22. George D, et al. Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-­resistant depression. Am J Geriatr Psychiatry 2017; 25:1199–1209.
23. Glue P, et al. Dose-­ and exposure-­response to ketamine in depression. Biol Psychiatry 2011; 70:e9–e10; author reply e11–e12.
24. Cusin C, et al. Long-­term maintenance with intramuscular ketamine for treatment-­resistant bipolar II depression. Am J Psychiatry 2012; 169:868–869.
25. Arabzadeh S, et al. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-­ blind controlled trial. J Affect Disord 2018; 235:236–241.
26. Domany Y, et al. Repeated oral ketamine for out-­patient treatment of resistant depression: randomised, double-­blind, placebo-­controlled, proof-­of-­concept study. Br J Psychiatry 2019; 214:20–26.
27. Rosenblat JD, et al. Oral ketamine for depression: a systematic review. J Clin Psychiatry 2019; 80:18r12475.
28. Swainson J, et al. Sublingual ketamine: an option for increasing accessibility of ketamine treatments for depression? J Clin Psychiatry 2020; 81:19lr13146.
29. Nguyen L, et al. Off-­label use of transmucosal ketamine as a rapid-­acting antidepressant: a retrospective chart review. Neuropsychiatr Dis Treat 2015; 11:2667–2673.
30. Lara DR, et al. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol 2013; 16:2111–2117.

Depression and anxiety disorders CHAPTER 3 31. Canuso CM, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-­blind, randomized, placebo-­controlled study. Am J Psychiatry 2018; 175:620–630. 32. Daly EJ, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-­resistant depression: a randomized clinical trial. JAMA Psychiatry 2018; 75:139–148. 33. Popova V, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-­ resistant depression: a randomized double-­blind active-­controlled study. Am J Psychiatry 2019; 176:428–438. 34. Daly EJ, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-­resistant depression: a randomized clinical trial. JAMA Psychiatry 2019; 76:893–903.